1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Irribow (ramosetron) is a product that was developed and is marketed by Astellas Pharma, and is available only in Japan for the treatment of males with IBS-D. In July 2014, Astellas announced that it had submitted an sNDA for Irribow for the treatment of females with IBS-D to the Ministry of Health, Labor and Welfare (MHLW) in Japan (Astellas Pharma, press release, July 14, 2014).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Irribow including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Irribow for the top country from 2013 to 2023.
- Sales information covered for Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Irribow performance.
- Obtain sales forecast for Irribow from 2013-2023 in top country (Japan).

Table Of Contents

Irribow (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.2 Classification 11
3.3 Symptoms 12
3.4 Prognosis 13
3.5 Quality of Life 13
4 Disease Management 14
4.1 Diagnosis and Treatment Overview 14
4.1.1 Diagnosis 14
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 16
4.1.3 Clinical Practice 19
5 Competitive Assessment 21
5.1 Overview 21
6 Irribow (ramosetron) 23
6.1 Overview 23
6.2 Efficacy 24
6.3 Safety 25
6.4 SWOT Analysis 26
6.5 Forecast 26
7 Appendix 28
7.1 Bibliography 28
7.2 Abbreviations 31
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 Diagnosed IBS Patients 33
7.4.2 General Pricing Assumptions 34
7.4.3 Individual Drug Assumptions 35
7.4.4 Generic Erosion 35
7.5 Primary Research - KOLs Interviewed for This Report 36
7.6 Primary Research - Prescriber Survey 38
7.7 About the Authors 39
7.7.1 Analyst 39
7.7.2 Therapy Area Director 39
7.7.3 Global Head of Healthcare 40
7.8 About GlobalData 41
7.9 Disclaimer 41

1.1 List of Tables

Table 1: Common Symptoms of IBS 12
Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS 15
Table 3: Treatment Guidelines for IBS 17
Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014† 18
Table 5: Leading Branded Treatments for IBS, 2014 22
Table 6: Product Profile - Irribow 24
Table 7: Irribow SWOT Analysis, 2014 26
Table 8: Global IBS Sales Forecasts ($m) for Irribow, 2013-2023 27
Table 9: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 38

1.2 List of Figures

Figure 1: Summary of Pharmacotherapies Used to Treat IBS 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Gastroesophageal Reflux Disease (GERD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Gastroesophageal ...

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Anti Peptic Ulcer Drugs Markets in China

Anti Peptic Ulcer Drugs Markets in China

  • $ 4000
  • Industry report
  • January 2017
  • by Asia Market Information & Development Company

China’s demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...


Download Unlimited Documents from Trusted Public Sources

Gastrointestinal Drug Industry in the US - Forecast

  • January 2017
    4 pages
  • Gastrointestina...  

    Digestive Syste...  

    Hormone  

  • United States  

View report >

Gastrointestinal Drug Industry in the US

  • January 2017
    8 pages
  • Gastrointestina...  

    Digestive Syste...  

  • United States  

View report >

Gastrointestinal Drug Markets in the US

  • January 2017
    11 pages
  • Gastrointestina...  

    Digestive Syste...  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.